|
|
Volumn 372, Issue 20, 2015, Pages 1964-1965
|
|
The authors reply
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR 3;
PERTUZUMAB;
PLACEBO;
TRASTUZUMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
TAXOID;
BREAST CANCER;
BREAST METASTASIS;
CANCER MORTALITY;
CANCER RECURRENCE;
CLINICAL PRACTICE;
EARLY CANCER;
HAZARD RATIO;
HUMAN;
LETTER;
OBSERVATIONAL STUDY;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
TREATMENT DURATION;
TREATMENT OUTCOME;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
DRUG EFFICACY;
BREAST NEOPLASMS;
FEMALE;
NEOPLASM METASTASIS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
FEMALE;
HUMANS;
NEOPLASM METASTASIS;
TAXOIDS;
|
|
EID: 84929332903
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1503446 Document Type: Letter |
|
Times cited : (15)
|
|
References (2)
|
